An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 20 Dec 2010 Actual end date changed from Oct 2009 to Nov 2009 as reported by ClinicalTrials.gov.
- 25 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2009 Planned end date changed from 1 Sep 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History